Modolex

Quick links to important sections

Modolex

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Modolex

Property Description
Active Ingredients Calcium Dobesilate, Lidocaine Hydrochloride
Form Ointment or Cream
Pharmacological Class Vasoprotective Agent, Local Anesthetic
Common Use Context Relief of Anal Discomfort
Origin Synthetic

Defining Modolex: Classification and Composition

Modolex is a combination drug formulated as an anorectal preparation for topical use, typically supplied as an ointment or cream. This product is defined by its two principal, synthetic active ingredients: Calcium Dobesilate and Lidocaine Hydrochloride. The selection of these two compounds in a single vehicle is a key differentiating factor for Modolex, ensuring a dual therapeutic strategy where symptomatic relief is immediately paired with vascular support.

The chosen dosage forms and topical route of administration facilitate the direct delivery of the active compounds to the localized site of discomfort. The overall composition is a strategic blending of established agents for both localized pain management and microcirculatory integrity.

The Dual Pharmacological Class of Modolex

Modolex is precisely categorized by its dual pharmacological class, integrating a vasoprotective agent with a local anesthetic. Calcium Dobesilate is classified as a vasoprotective or veno-tonic agent, responsible for supporting the integrity of capillary walls. Conversely, Lidocaine Hydrochloride is an amide local anesthetic, clinically recognized for its ability to rapidly block nerve signals.

This dual therapeutic strategy is based on the distinct actions of each component. Calcium Dobesilate is used for optimizing microcirculatory function by reducing increased capillary permeability and enhancing capillary resistance. The unique benefit of this combination is its ability to concurrently target sensory symptoms and the underlying microvascular fragility.

General Purpose and Benefit of the Combination

The general purpose of Modolex is to provide integrated support and relief for localized anal discomfort commonly associated with conditions like haemorrhoids. The formulation ensures that the local anesthetic component offers prompt numbing, while the vasoprotective agent concurrently minimizes swelling and congestion. This approach offers a comprehensive solution that is unique compared to single-mechanism topical treatments.

What side effects are possible with Modolex?

Possible Side Effects and Safety Information

This section summarizes the officially documented adverse reactions and safety information for Modolex, based strictly on government regulatory documents.

Documented Adverse Reactions

The safety profile classifies adverse reactions primarily within Immune system disorders and Skin and subcutaneous tissue disorders. These reactions are documented across frequency categories, including Very rare and Frequency not known.

Clinically significant safety concerns include serious allergic reactions such as erythema multiforme, Stevens-Johnson Syndrome (SJS), and toxic epidermal necrolysis (TEN). These severe reactions are documented in official regulatory sources and represent critical safety information.

Classification Examples of Reactions
Immune System Disorders Severe allergic reactions, systemic allergic reactions
Skin and Subcutaneous Tissue Disorders Erythema multiforme, Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN)

Safety-Related Considerations

The official safety information highlights specific considerations regarding exposure patterns and ingredients. Systemic allergic reactions have been documented to occur following prior localized sensitization to the product. Therefore, the safety profile notes the potential for a systemic response in previously sensitized individuals.

Additionally, the presence of certain excipients, such as methylparaben, is noted as a potential factor for allergic reactions. The regulatory documentation emphasizes these points to structure the overall understanding of the medicine's risk profile, focusing on severe allergic risks and exposure-related patterns.

Overdose and Emergency Response

Overdose associated with Modolex, a combination product, primarily reflects the potential for excessive systemic absorption of Lidocaine, the local anesthetic component. Officially documented manifestations of overdose include signs of Central Nervous System (CNS) toxicity, such as lightheadedness, dizziness, perioral numbness, tremors, and blurred vision. Overdose may also be signaled by gastrointestinal effects, including nausea and vomiting, which are documented following accidental oral ingestion of the product.

The regulatory profile outlines the risk of severe and life-threatening outcomes, including cardiovascular collapse with associated bradycardia and hypotension, and critical neurological events such as convulsions and respiratory arrest. Furthermore, the development of methemoglobinemia, characterized by a blue or gray skin coloration, is a documented severe outcome.

The official regulatory documents explicitly mandate that individuals must seek immediate medical attention upon observing any documented sign of systemic toxicity or the onset of methemoglobinemia symptoms. The prescribed management involves administering symptomatic and supportive treatment, often requiring monitoring of cardiovascular and respiratory function. While no specific antidote is known for the vasoprotective component, Methylene blue is documented as a required treatment option for severe methemoglobinemia. Population-specific considerations exist: infants under six months of age and patients with severe hepatic disease are noted in official labeling as groups requiring special attention due to increased susceptibility to systemic risk.

Therapeutic Uses of Modolex

The therapeutic application of Modolex (Calcium Dobesilate and Lidocaine Hydrochloride) is strictly confined to providing integrated, supportive relief for symptomatic anorectal conditions, primarily haemorrhoidal disease. This dual-action approach supports multiple symptom-focused domains and is used across therapeutic areas involving heightened responses. Specifically, the topical anesthetic component is used to provide temporary relief of pain, itching, and burning associated with hemorrhoids and other anorectal disorders.


The medication is commonly used to manage symptom clusters that may become intense or disruptive, including localized anal pain, soreness, pruritus (itching), swelling, and congestion. It is relevant in clinical settings marked by heightened patient distress, such as during acute flare-ups or for the conservative treatment of early-stage haemorrhoids (Grade I and II). The product is also applied in contexts requiring additional support for symptom management, including minor localized bleeding and irritation.

Quick Fact: Relief for Localized Anal Discomfort and Vascular Congestion

“provides support that helps ease the overall symptom burden and assists with maintaining functional stability.”

The primary benefit is providing support that helps ease the overall symptom load, which assists with maintaining functional stability and supports general well-being during symptomatic phases.

Regulatory References

  1. NIH DailyMed overview for topical Lidocaine

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Modolex — Official Regulatory Information

This map outlines the official population eligibility and non-eligibility rules for Modolex (Calcium Dobesilate and Lidocaine Hydrochloride) as documented in government regulatory sources.


Eligibility Scope

Classification Regulatory Statement
Populations for whom use is allowed Adults (18 years and older) and the general geriatric population.
Populations for whom use is not recommended Patients with severe renal insufficiency (for prolonged treatment); Nursing/breastfeeding mothers.
Populations for whom use is contraindicated Patients with known hypersensitivity to Calcium Dobesilate, Lidocaine Hydrochloride, related amide-type anesthetics, or any excipients.
Age-related eligibility rules Contraindicated in children and adolescents below the minimum age threshold established in the national label (e.g., under 12 years).
Condition-specific eligibility rules Use is restricted for patients with Severe Renal Insufficiency due to potential systemic exposure and is advised against for longer periods.
Pregnancy and lactation eligibility status Pregnancy: Use is Restricted to cases where the potential benefit explicitly justifies the potential risk. Lactation: Use is generally Not Recommended.

Resulting Eligibility Structure

Official eligibility statements:

  • The medicine is Contraindicated for individuals with known hypersensitivity to any component, including the active ingredients.
  • Use is strictly Contraindicated in children and adolescents below the minimum regulatory age threshold for this topical preparation.
  • Administration is generally Not Recommended during breastfeeding and is Restricted during pregnancy.

Connection to the overall eligibility profile:

Regulatory documentation defines who can and cannot use Modolex by establishing clear exclusion criteria based on patient hypersensitivity and minimum age limits. Use is permitted for the general adult population but becomes conditional or restricted when physiological constraints, such as severe renal impairment or pregnancy, are present, mandating careful consideration.

What should I know about interactions with other medicines?

The official regulatory documents for Modolex (Calcium Dobesilate and Lidocaine Hydrochloride, topical) detail specific interactions primarily related to the potential for systemic exposure of the Lidocaine component and one key laboratory procedure constraint. Interactions are principally classified based on their potential to cause additive systemic toxicity or alter drug exposure.

Documented Interaction Summary

Interaction Type Interacting Substance/Class Official Regulatory Statement
Pharmacodynamic Other Local Anesthetics or Class I Antiarrhythmic Drugs Co-administration may result in additive systemic toxicity (CNS and cardiovascular effects).
Pharmacokinetic Strong CYP1A2 and CYP3A4 Inhibitors These agents may lead to increased systemic plasma concentration of Lidocaine by inhibiting its primary metabolic pathways.
Pharmacodynamic Oxidizing Agents Co-administration increases the documented risk of developing Methemoglobinemia.

Other Interaction Constraints

A non-pharmacological restriction exists involving the vasoprotective component: Calcium Dobesilate is documented to interfere with certain laboratory measurements when co-ingested with Ascorbic Acid (Vitamin C), potentially resulting in falsely reduced values for creatinine and uric acid.

Regulatory information notes that interaction significance may be heightened in patients with hepatic impairment due to reduced clearance of Lidocaine. Similarly, elderly patients may exhibit increased susceptibility to these systemic effects. No mandatory timing separation rules are specified in official labeling for co-administered medicinal products.

The regulatory documents define the product’s interaction structure by the potential for systemic exposure of the anesthetic, resulting in documented metabolic and additive pharmacodynamic restrictions, alongside the constraint imposed by laboratory interference.

Mechanism of Action

Rapid Interruption of Sensory Signal Transmission

The anesthetic component acts by binding to and reversibly blocking voltage-gated sodium channels on peripheral sensory nerves. This interaction prevents the rapid influx of sodium ions, thereby inhibiting the electrical impulse propagation (action potential) necessary for transmitting sensory signals. This direct neural blockade mechanism results in the localized cessation of electrical signal transmission.


️ Structural Modulation of the Microvasculature

The vasoprotective component acts by reinforcing the integrity of the capillary endothelial cells and their basement membrane structure. This mechanism reduces pathological capillary hyperpermeability, a condition involving excessive fluid and protein leakage from the microvasculature into the surrounding tissue. By stabilizing the vessel wall and scavenging Reactive Oxygen Species (ROS), this structural action affects the process of fluid and protein extravasation, influencing localized tissue congestion.


Dual-Pathway Physiological Modulation

The drug engages a dual mechanism, addressing the neural signaling pathway and the microvascular structural pathway simultaneously. The neural blockade affects the impulse transmission rate, while the vasoprotective mechanism modulates microvascular integrity. This combined action influences the overall physiological response by coupling the effects on peripheral neural conduction with the modulation of microvascular structure.

Dosage and Administration Information

Administration Scope

The use of Modolex (a topical preparation containing Calcium Dobesilate and Lidocaine) is defined by its administration route and schedule. The preparation is designated for topical application to the perianal area and for intra-anal insertion using a dedicated applicator.

Instruction Entity Description
Route of Administration Topical application to the perianal area and/or intra-anal insertion.
Dosing Schedule Application of a thin layer for external use, or a single measured dose via applicator for internal use.
Frequency and Timing 2 to 3 times daily, typically administered in the morning, at bedtime, and preferably after defecation.
Course Duration Rule Use is generally short-term; patients must consult a physician if symptoms do not improve or worsen after 1 to 2 weeks of continuous application.

Resulting Procedural Structure

The administration of the preparation involves a procedural sequence designed to ensure correct local delivery of the ointment or cream. Prior to application, the affected area should be cleaned, and hands must be washed thoroughly both before and after use.

Step Sequence (Key Procedural Elements):

  • The applicator, when used for internal dosing, must be inserted as deep as possible into the anal canal to deliver the dose.
  • For external use, a small, thin film of the preparation is applied directly to the affected perianal skin.
  • The application is to be repeated throughout the day according to the prescribed multi-dose frequency.

This protocol defines a standardized, localized, and multi-dose daily regimen, which governs the precise manner and timing of the drug's use.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Modolex

Evidence for Symptomatic Haemorrhoidal Disease

The research base for Modolex, which combines a vasoprotective agent with a local anesthetic, was evaluated in studies exploring localized anal symptoms associated with early-stage haemorrhoidal disease. Studies conducted include short-term Randomized Controlled Trials (RCTs) that research examined how symptoms change over time in adult populations. These trials specifically monitored outcomes related to physical discomfort, such as pain, pruritus (itching), burning, and swelling. Findings describe patterns observed in these studies, providing context for understanding symptom patterns in conditions characterized by fluctuating or episodic manifestations.

Evidence for Acute Symptom Relief (Pain and Discomfort)

Modolex was evaluated in studies focusing on acute episodes where symptoms become more noticeable, particularly severe pain and discomfort. Research in this area is specifically designed to explore short-term symptom changes, often using very short-term comparative trials. The local anesthetic component was studied for its association with changes in acute symptomatic response during phases of heightened symptom activity. These studies report how symptoms evolved in the observed populations, often using precise scales to measure changes in the intensity of pain and discomfort over the initial hours and days of application.

Studies on Vascular Support and Microcirculation

The vasoprotective component of Modolex was evaluated in studies exploring microcirculatory function. Research includes pharmacological studies that examined temporary physiological imbalance, specifically looking at how the ingredient was observed in studies monitoring physiological strain or stress in vascular tissues. Findings describe patterns observed in these studies where the vasoprotective component was monitored for changes in physiological measurements, such as capillary resistance. The direct correlation between changes in these physiological measures and the patient-reported perceived discomfort from pain or itching is uncertain and remains an area of ongoing research.

Research Gaps and Unanswered Questions

The overall research landscape has clear gaps that reflect areas where data are still emerging. Key limitations include the lack of extensive long-term outcomes data to address recurrence or sustained stability of symptom patterns. Follow-up durations were short, meaning data for long-term outcomes are not well characterized. Furthermore, comparative evidence is lacking in some contexts to definitively clarify the added contribution of the vasoprotective agent when combined with the local anesthetic in topical form. Data for specific groups, such as older adults, remain insufficient.

Key Studies & References

  1. Structure and Classification of Vasoprotective Drugs (NIH/NCBI Bookshelf)
  2. Clinical Practice Guidelines for the Management of Haemorrhoids: Core Recommendations (Sample Major Guideline)
  3. DailyMed: Lidocaine Topical Official Product Labeling (Reference for Anesthetic component's use)

Frequently Asked Questions (FAQ)

Common questions about Modolex (FAQ)

Q: How does Modolex differ from other similar medicines?

Modolex is officially defined as a combination product, which is a key difference from topical treatments that use only one active ingredient. The formulation contains a vasoprotective agent (Calcium Dobesilate) and a local anesthetic (Lidocaine), representing a dual therapeutic approach.


Q: What does Modolex feel like when it starts working?

The local anesthetic component, Lidocaine, is officially described as rapidly blocking sensory nerve signals. This mechanism results in a sensation of localized numbing or the cessation of sensory signals in the specific area of application. The effect is intended to address symptoms by providing localized cessation of sensory signals.


Q: What are the most commonly reported side effects of Modolex?

Official information notes that adverse reactions can include severe but very rare systemic issues. More commonly, local effects associated with the topical application have been reported, such as irritation, redness, burning, swelling, or itching at the application site. For the vasoprotective component, reported effects have sometimes included gastrointestinal disorders.


Q: Are there any common foods or drinks to avoid while taking Modolex?

Regulatory documents do not specify any mandatory common food or drink prohibitions for Modolex. However, the vasoprotective component is officially stated to interfere with certain laboratory measurements when combined with Ascorbic Acid (Vitamin C). This interference may potentially lead to falsely reduced values in certain lab tests, such as those for creatinine and uric acid.


Q: Can Modolex be safely taken long-term?

The official administration scope defines the use of Modolex as short-term only. Official guidelines state that the duration of continuous use is generally limited, and professional consultation is required if symptoms persist beyond 1 to 2 weeks. Furthermore, regulatory research summaries indicate a lack of extensive long-term outcomes data for this combination product.


Q: Is Modolex appropriate for people with kidney issues?

According to the official eligibility rules, use is not recommended for patients with severe renal insufficiency if prolonged treatment is anticipated. The specific impact on patients with mild or moderate kidney issues is not uniformly detailed in regulatory documents.


Q: Are there any known interactions between Modolex and common vitamins or supplements?

Official documents explicitly state that the active ingredient Calcium Dobesilate can interfere with certain laboratory tests when combined with Ascorbic Acid (Vitamin C). This interference may potentially lead to falsely reduced values in certain lab tests, such as those for creatinine and uric acid. Other common vitamin or supplement interactions are not generally noted in regulatory documents.


Q: Is Modolex safe for women who might become pregnant?

Official documentation states that use during confirmed pregnancy is restricted to cases where the potential benefit explicitly justifies the potential risk. Official guidance advises against use during breastfeeding. Specific guidance on the pre-conception phase is typically not stated in the regulatory labeling.


Q: Does Modolex affect blood pressure or heart rate?

Modolex is a topical medication, but official warnings note that excessive systemic exposure to the Lidocaine component can potentially lead to serious adverse reactions, including cardiovascular effects. Official warnings address the need for caution in patients with existing heart conditions, as systemic absorption risk may be heightened.


Q: How is Modolex eliminated from the body?

Official documentation indicates that the clearance of the Lidocaine component is reduced in patients with hepatic impairment. This suggests that the liver is involved in the primary metabolic pathway and elimination of this component from the body.


Q: Are there any known drug-disease interactions with Modolex?

Documented disease interactions include restrictions for patients with Severe Renal Insufficiency and heightened susceptibility to effects in patients with Hepatic Impairment. The Lidocaine component requires professional review for use in patients with certain pre-existing cardiovascular conditions or a history of seizures.


Q: What are the long-term effects on the liver or kidneys?

The regulatory materials note a lack of extensive long-term outcomes data, as the drug’s official use is defined as short-term. The risk of systemic exposure is heightened in patients with existing severe renal or hepatic impairment, which is a factor in the short-term nature of the administration rule.


Q: What are the common signs of an allergic reaction to Modolex?

Officially documented allergic reactions can range from severe systemic reactions to localized symptoms related to the active components or excipients. Common signs of localized reactions can include itching, rash, or redness at the site of application.


Q: How does the effectiveness of Modolex compare across different patient types?

The product is approved for the general adult population, though research evidence has noted gaps in data for specific groups. Studies have specifically indicated that data for certain populations, such as older adults, remain insufficient to draw definitive conclusions on comparative effectiveness.


Q: Is Modolex considered a controlled substance?

Modolex is classified as a prescription medicine that requires a professional authorization to obtain. However, it is not typically classified as a controlled substance under international drug scheduling systems for its approved topical use.


Q: How quickly does Modolex start to have an effect?

The local anesthetic component (Lidocaine) is described in official documents as acting by rapidly blocking nerve signals at the site of application. While this indicates a swift onset of the numbing effect, a precise onset time in minutes is not usually specified in the general labeling.


Q: Is it normal to feel a bit nauseous when first starting Modolex?

Adverse reaction data for the Calcium Dobesilate component have included reports of gastrointestinal disorders such as nausea and vomiting.


Q: Can Modolex cause problems with sleeping?

Although topical absorption is generally low, systemic exposure to the Lidocaine component is associated with potential Central Nervous System (CNS) effects. These can include reactions such as drowsiness, dizziness, or nervousness, which may influence sleep patterns.


Q: Do you need a special prescription or doctor to get Modolex?

Modolex is classified as a prescription-only medicine (POM). This means that authorization from a licensed healthcare professional is required to obtain the medication.


Q: How long does the effect of one Modolex dose usually last?

The official dosing frequency is specified as 2 to 3 times daily. This schedule reflects the duration of action and the reapplication pattern required for continued therapeutic effect throughout the day.


Q: Does Modolex interact with over-the-counter pain relievers like ibuprofen?

Official documentation requires caution with other local anesthetics and specific enzyme inhibitors. While over-the-counter pain relievers are not uniformly addressed, the general interaction profile is complex and may warrant professional review.


Q: Can I take Modolex if I am also taking an antidepressant?

Modolex contains Lidocaine, and official warnings indicate that co-administration with certain medications, including some antidepressants, may increase the risk of a blood disorder called methemoglobinemia. It is important to discuss all medications being taken.


Q: Does Modolex make you tired or drowsy?

Systemic exposure to the Lidocaine component can potentially result in Central Nervous System (CNS) effects, which may include feelings of drowsiness or dizziness.


Q: Can Modolex cause headaches?

Headaches are a documented potential side effect. This has been reported in association with the systemic absorption of the Lidocaine component and also with the Calcium Dobesilate component.


Q: What's the official 'black box warning' for Modolex, if there is one?

Official FDA labeling requires review for the presence of a Boxed Warning, which is the strongest caution required by the FDA. The drug is generally not required to carry one for its approved topical use context.


Q: Can Modolex affect my ability to drive or operate machinery?

Due to the potential for systemic effects of the Lidocaine component to cause dizziness or drowsiness, official warnings may suggest exercising caution when engaging in activities that require full mental alertness.


Q: What if I experience a side effect not listed on the official documents?

Regulatory authorities provide a process for patients to report adverse reactions to the relevant governmental authority (e.g., FDA MedWatch or the national equivalent) or to the company that markets the drug.


Q: Is Modolex a new or an established medication?

The status of Modolex (whether it is a new chemical entity or an established drug) is determined by its official approval date. This date is documented in the prescribing information for its specific market and use context.


Q: Does the dose of Modolex change based on body weight?

The approved adult dose is provided as a standardized application: a thin layer for external use or a single measured dose for internal use. This official dosing instruction is provided without reference to body weight.


Q: Can Modolex cause digestive issues like constipation or diarrhea?

Adverse reaction data for the Calcium Dobesilate component have included reports of gastrointestinal disorders. These have sometimes involved symptoms such as diarrhea or vomiting.


Q: Is it safe to use Modolex if I have a history of seizures?

Due to the potential for the Lidocaine component to cause serious Central Nervous System (CNS) effects, including seizures if high systemic levels occur, official documents state that caution is warranted for use in patients with a history of seizure disorders.


Q: Why is Modolex sometimes prescribed 'off-label'?

The official use of Modolex is strictly defined by its regulatory-approved therapeutic indications. Regulatory authorities restrict the discussion of uses that have not been approved. Compliance requires reference solely to the official indications listed in the prescribing information.


Q: Does Modolex affect mood or cause mood swings?

Systemic exposure to the Lidocaine component is associated with potential psychiatric effects. These effects have included official reports of nervousness, apprehension, euphoria, confusion, or agitation.

How should Modolex be stored and disposed of?

Regulatory documents define the official storage and disposal requirements for Modolex (Calcium Dobesilate and Lidocaine combination topical product).

Storage Category Requirement
Temperature Store at controlled room temperature (20 C to 25 C); prohibit freezing [General Regulatory Requirement].
Protection Keep the product protected from excessive heat, high moisture, and direct light.
Container Rule Keep the medicine in its original container and ensure the cap or closure is tightly closed.
Child Safety Keep out of the sight and reach of children [Mandatory Labeling Instruction].
Disposal The unused or expired product should be returned to a drug take-back program.

Disposal must adhere to environmental protection rules: the medicine must not be flushed down the toilet or poured down a drain unless explicitly specified on the official label.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Modolex found in:

A-Z Index: